Allegra Orthopaedics (ASX:AMT) - CEO, Jenny Swain (left)
CEO, Jenny Swain (left)
Source: MTP Connect
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Allegra Orthopaedics (AMT) has secured a loan facility of up to $2 million to progress the company’s Bone Substitute Project
  • The orthopaedic solutions provider is developing a composite biocompatible ceramic material known as Sr-HT-Gahnite
  • Substantial shareholder Robinwood Investments will loan the funds, which may be drawn down in tranches of $300,000 over a two-year term
  • The loan enables AMT to pursue commercialisation, including gaining regulatory approvals from the U.S. Federal Drug Administration and Australia’s Therapeutic Goods Administration
  • Allegra Orthopaedics shares last traded at 32 cents each

Allegra Orthopaedics (AMT) has secured a loan facility of up to $2 million to progress the company’s Bone Substitute Project.

The orthopaedic solutions provider is developing a composite biocompatible ceramic material known as Sr-HT-Gahnite.

Allegra’s substantial shareholder Robinwood Investments will loan the funds, which may be progressively drawn down in tranches of $300,000, as required, over a two-year term.

This will enable Allegra to pursue commercialisation, including gaining regulatory approvals from both the Federal Drug Administration in the U.S. and Australia’s Therapeutic Goods Administration

The loan carries a 13 per cent annual interest rate on all cumulative amounts drawn down, with interest to be paid monthly in arrears.

Further, should Allegra decide to raise capital during the loan term, it may offer the lender the option to convert any or all of the current loan balance to shares.

If Robinwood does not take up the offer in full, however, any loan balances outstanding at the end of the term may be converted to Allegra shares, subject to shareholder approval.

Here, the conversion price would represent a 10 per cent discount to the 90-day volume-weighted average price.

Alternatively, AMT may repay the outstanding balance to the lender.

Allegra Orthopaedics shares are in the grey, last trading at 32 cents each at 4:51 pm AEST.

AMT by the numbers
More From The Market Online

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…

Little Green Pharma closely eyeing USA’s legal downgrade of Cannabis danger

Overnight, the Biden government did something sure to give their counterparts a stir – the USA…

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…